Path, a nonprofit global health organization, received a $27.3 million cost-plus-fixed-fee prime contract from the U.S. Agency for International Development (USAID) to support innovations in malaria vaccine development (IMV). The contract aims to advance the proof of concept of vaccines that reduce morbidity and mortality from Plasmodium falciparum malaria, with a target efficacy of at least 75% and evidence of affordability. Path is partnering with subcontractors including the University of Oxford, Statens Serum Institute, Scripps Research Institute, and the University of Texas at Austin to support preclinical development through proof-of-concept clinical studies of next-generation malaria vaccines targeting pre-erythrocytic and blood-stage antigens. No set-aside designation was applied to this award made under USAID's Malaria Vaccine Development Program to enhance investments through a collaborative design process.
Generated 3/6/24, 12:05 PM